BioCentury | Feb 24, 2014
Company News

BioAtla, BioMotiv deal

...commercialize an IL-22 mAb to treat inflammatory bowel disease (IBD) and cancer. BioMotiv launched newco Kodosil Bio LLC...
...all compounds resulting from the deal. The companies will partner for discovery and preclinical development. Kodosil Bio...
...the program through early clinical development, after which it will seek to partner the program. Kodosil Bio...
Items per page:
1 - 1 of 1
BioCentury | Feb 24, 2014
Company News

BioAtla, BioMotiv deal

...commercialize an IL-22 mAb to treat inflammatory bowel disease (IBD) and cancer. BioMotiv launched newco Kodosil Bio LLC...
...all compounds resulting from the deal. The companies will partner for discovery and preclinical development. Kodosil Bio...
...the program through early clinical development, after which it will seek to partner the program. Kodosil Bio...
Items per page:
1 - 1 of 1